Skip to main content
. Author manuscript; available in PMC: 2019 Jul 29.
Published in final edited form as: Alcohol. 2017 Aug 30;64:37–43. doi: 10.1016/j.alcohol.2017.05.006

Fig. 4.

Fig. 4.

Co-application of protein kinase inhibitor KT-5720 (1 mM) and ethanol (i.e., 50 mM) attenuated the loss of NeuN/Fox-3 IR produced by CIE exposure in the granule cell layer of the DG. Data are presented as percent control of the mean ± SEM. **Statistical significance (p < 0.05) compared to control-treated hippocampi; #statistical significance (p < 0.05) compared to drug-naïve, ethanol-treated hippocampi. N ¼ 40 for ethanol-treated hippocampi; N ¼ 40 for hippocampi treated with ethanol and KT during EWD; N ¼ 40 for hippocampi treated with ethanol and KT concomitantly; N ¼ 38 for control-treated hippocampi; N ¼ 36 for control-treated hippocampi with KT applied during the EWD period; N ¼ 25 for control-treated hippocampi with KT applied during CIE.